Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) have been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $52.50.
A number of brokerages recently weighed in on AGIO. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $60.00 to $56.00 in a research report on Friday, September 27th. StockNews.com lowered shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 19th.
Get Our Latest Stock Report on AGIO
Insider Activity at Agios Pharmaceuticals
Hedge Funds Weigh In On Agios Pharmaceuticals
A number of hedge funds have recently made changes to their positions in AGIO. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth $37,000. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth about $40,000. North Star Asset Management Inc. acquired a new position in Agios Pharmaceuticals during the second quarter worth about $216,000. XTX Topco Ltd purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at about $230,000. Finally, Northcape Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $244,000.
Agios Pharmaceuticals Trading Down 2.9 %
Shares of AGIO stock opened at $40.56 on Friday. Agios Pharmaceuticals has a twelve month low of $19.80 and a twelve month high of $53.28. The stock has a fifty day simple moving average of $45.34 and a two-hundred day simple moving average of $40.02. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -6.42 and a beta of 0.75.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $9.34 million. During the same period last year, the company earned ($1.51) earnings per share. The firm’s revenue was up 28.4% compared to the same quarter last year. Research analysts predict that Agios Pharmaceuticals will post -4.85 EPS for the current fiscal year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Read More
- Five stocks we like better than Agios Pharmaceuticals
- The 3 Best Blue-Chip Stocks to Buy Now
- When Is the Best Time to Invest in Mutual Funds?
- How to Calculate Return on Investment (ROI)
- Is NVIDIA Stock in a Correction or Consolidation?
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.